Recent progress on the topical therapy of onychomycosis

Bibliography

• GHANNOUM MA, HAJJEH RA, SCHER R et al.: A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J. Am. Acad. Dermatol. (2000) 43(4):641-648.
   PubMed Web of Science ®Google Scholar
• ELEWSKI B, CHARIF MA: Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch. Dermatol. (1997) 133:1172-1173.
   PubMed Web of Science ®Google Scholar
• HOSSAIN MA, GHANNOUM MA: New developments in chemotherapy for non-invasive fungal infections. Expert Opin. Investig. Drugs (2001) 10(8):1501-1511.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, JAIN HC, LYNDE CW et al.: Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter Canadian survey of 15,000 patients. J. Am. Acad. Dermatol. (2000) 43:244-248.
   PubMed Web of Science ®Google Scholar
• SHEAR NH, GUPTA AK: Terbinafine for the treatment of pedal onychomycosis. A foot closer to the promised land of cured nails. Arch. Dermatol. (1995) 131:937-942.
   PubMed Web of Science ®Google Scholar
• HABIF TB: Nail diseases. In: Clinical dermatology. Chapter 25, Habif TB (Ed.), Mosby, Inc., Philadelphia, USA (2004) 4:875.
   Google Scholar
• SCHER RK, BARAN R: Onychomycosis in clinical practice: factors contributing to recurrence. Br. J. Dermatol. (2003) 149(Suppl. 65):5-9.
   PubMed Web of Science ®Google Scholar
• ARRESE JE, PIÉRARD GE: Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology (2003) 207:255-260.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, LYNCH LE: Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. Cutis (2004) 74(Suppl. 1):10-15.
   PubMed Web of Science ®Google Scholar
• TOSTI A, PIRACCINI BM, STINCHI C et al.: Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology (1998) 197:162-166.
   PubMed Web of Science ®Google Scholar
• MURDAN S: Drug delivery to the nail following topical application. Int. J. Pharm. (2002) 236:1-26.
   PubMed Web of Science ®Google Scholar
• GUPCHUP GV, ZATZ JL: Structural characteristics and permeability properties of the human nail: a review. J. Cosmet. Sci. (1999) 50:363-385.
   Web of Science ®Google Scholar
• STÜTTGEN G, BAUER E: Bioavailability, skin- and nail penetration of topically applied antimycotics. Mykosen (1982) 25:74-80.
   PubMedGoogle Scholar
• HANEKE E: Fungal infections of the nail. Semin. Dermatol. (1991) 10:41-53.
   PubMedGoogle Scholar
• MERTIN D, LIPPOLD BC: In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: influence of the partition coefficient octanol/water and the water solubility of drugs on their permeability and maximum flux. J. Pharm. Pharmacol. (1997) 49:30-34.
   PubMed Web of Science ®Google Scholar
• WALTERS KA, FLYNN GL, MARVEL JR: Physiochemical chemical characterization of the human nail: permeation pattern for water and the homologous alcohols and the difference with respect to stratum corneum. J. Pharm. Pharmacol. (1983) 35:28-33.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI Y, MIYAMOTO M, SUGIBAYASHI K et al.: Drug permeation through the three layers of the human nail plate. J. Pharm. Pharmacol. (1999) 51:271-278.
   PubMed Web of Science ®Google Scholar
• SIGURGEIRSSON B, BILLSTEIN S, RANTANEN T et al.: L.I.O.N. study: efficacy and tolerability of continuous terbinafine (Lamisil®) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Br. J. Dermatol. (1999) 141(Suppl. 56):5-14.
   PubMed Web of Science ®Google Scholar
• DE CUYPER C, HINDRYCKX PH: Long-term outcomes in the treatment of toenail onychomycosis. Br. J. Dermatol. (1999) 141(Suppl. 56):15-20.
   PubMed Web of Science ®Google Scholar
• GHANNOUM MA, RICE LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. (1999) 12:501-517.
   PubMed Web of Science ®Google Scholar
• DE BACKER M, DE KEYSER P, DE VROEY C et al.: A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day versus itraconazole 200 mg/day – a double blind comparative trial. Br. J. Dermatol. (1996) 134(Suppl. 46):16-17.
   PubMed Web of Science ®Google Scholar
• BARAN R, GUPTA AK, PIÉRARD GE: Pharmacology of onychomycosis. Expert Opin. Pharmacother. (2005) 6(4):609-624.
   PubMed Web of Science ®Google Scholar
• RICHARDSON MD, WARNOCK DW: In: Fungal infections, diagnosis and management. Third Edition, Blackwell Publishing, Malden, USA (2003).
   Google Scholar
• WEINBERG ED: Antifungal agents. In: Principles of medicial chemistry. Chapter 35, Foye WO (Ed.), Leo & Febiger, Malvern, USA (1990) 3:731.
   Google Scholar
• GULL K, TRINCI AP: Griseofulvin inhibits fungal mitosis. Nature (1973) 244:292-294.
   PubMed Web of Science ®Google Scholar
• GUPTA AK: Ciclopirox: an overview. Int. J. Dermatol. (2001) 40:305-310.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, PLOTT T: Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int. J. Dermatol. (2004) 43(Suppl. 1):3-8.
   PubMedGoogle Scholar
• POLAK A: Mode of action of morpholine derivatives. Ann. NY Acad. Sci. (1988) 544:221-228.
   PubMedGoogle Scholar
• FANG FC: Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. (1997) 99(12):2818-2825.
   PubMed Web of Science ®Google Scholar
• BAKER SJ, ZHANG YK, AKAMA T et al.: Discovery of a new boron-containing anti-fungal agent, 5-fluoro-1,3- dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J. Med. Chem. (2006) 49:4447-4450.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, RYDER JE, BARAN R: The use of topical therapies to treat onychomycosis. Dermatol. Clin. (2003) 21:481-489.
   PubMed Web of Science ®Google Scholar
• ROBERTS DT: Onychomycosis: current treatment and future challenges. Br. J. Dermatol. (1999) 141(Suppl. 56):1-4.
   PubMed Web of Science ®Google Scholar
• BAKER SJ, HUI X, MAIBACH HI: Progress on new therapeutics for fungal nail infections. Ann. Rep. Med. Chem. (2005) 40:323-334.
   Web of Science ®Google Scholar
• KOBAYASHI Y, KOMATSU T, SUMI M et al.: In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur. J. Pharm. Sci. (2004) 21:471-477.
   PubMed Web of Science ®Google Scholar
• TATSUMI Y, YOKOO M, SENDA H et al.: Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob. Agents Chemother. (2002) 46:3797-3801.
   PubMed Web of Science ®Google Scholar
• HUI X, CHAN TCK, BARBADILLO S et al.: Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. J. Pharm. Sci. (2003) 92:142-148.
   PubMed Web of Science ®Google Scholar
• HUI X, BAKER SJ, WESTER RC et al.: In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J. Pharm. Sci. (2006) (In Press).
   PubMedGoogle Scholar
• COLOMBO B, FELICETTI L, BAGLIONI C: Inhibition of protein synthesis by cycloheximide in rabbit reticulocytes. Biochem. Biophys. Res. Commun. (1965) 18:389-395.
   PubMed Web of Science ®Google Scholar
• GROLLMAN AP: Inhibitors of protein biosynthesis. II. Mode of action of anisomycin. J. Biol. Chem. (1967) 242(13):3226-3233.
   PubMed Web of Science ®Google Scholar
• JUSTICE MC, HSU MJ, TSE B et al.: Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis. J. Biol. Chem. (1998) 273(6):3148-3151.
   PubMed Web of Science ®Google Scholar
• FULLER AT, MELLOWS G, WOOLFORD M et al.: Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens. Nature (1971) 234(5329):416-417.
   PubMed Web of Science ®Google Scholar
• NICHOLAS RO, BERRY V, HUNTER PA et al.: The antifungal activity of mupirocin. J. Antimicrob. Chemother. (1999) 43(4):579-582.
   PubMed Web of Science ®Google Scholar
• PETRAITIS V, PETRAITIENE R, KELAHER AM et al.: Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. Antimicrob. Agents Chemother. (2004) 48(10):3959-3967.
   PubMed Web of Science ®Google Scholar
• ZIEGELBAUER K: Decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance to the cyclic β-amino acid BAY 10-8888 in Candida albicans and Candida tropicalis. Antimicrob. Agents Chemother. (1998) 42(7):1581-1586.
   PubMed Web of Science ®Google Scholar
• ZIEGELBAUER K, BABCZINSKI P, SCHONFELD W: Molecular mode of action of the antifungal β-amino acid BAY 10-8888. Antimicrob. Agents Chemother. (1998) 42(9):2197-2205.
   PubMed Web of Science ®Google Scholar
• CAPOBIANCO JO, ZAKULA D, COEN ML et al.: Anti-Candida activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action. Biochem. Biophys. Res. Commun. (1993) 190(3):1037-1044.
   PubMed Web of Science ®Google Scholar
• HENDRICKSON TL, SCHIMMEL P: Transfer RNA-dependent amino acid discrimination by aminoacyl-tRNA synthetase. In: Translation mechanisms. Lapointe JPD, Brakier-Gingras L (Eds), Landes Bioscience, Georgetown, USA (2003):34-64.
   Google Scholar
• CUSACK S, YAREMCHUK A, TUKALO M: The 2 Å crystal structure of leucyl-tRNA synthetase and its complex with a leucyl-adenylate analogue. EMBO J. (2000) 19(10):2351-2361.
   PubMed Web of Science ®Google Scholar
• FUKAI S, NUREKI O, SEKINE S et al.: Structural basis for double-sieve discrimination of l-valine from l-isoleucine and l-threonine by the complex of tRNA(Val) and valyl-tRNA synthetase. Cell (2000) 103(5):793-803.
   PubMed Web of Science ®Google Scholar
• NUREKI O, VASSYLYEV DG, TATENO M et al.: Enzyme structure with two catalytic sites for double-sieve selection of substrate. Science (1998) 280(5363):578-582.
   PubMed Web of Science ®Google Scholar
• HUGHES J, MELLOWS G: Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthetase. Biochem. J. (1980) 191(1):209-219.
   PubMed Web of Science ®Google Scholar
• SILVIAN LF, WANG J, STEITZ TA: Insights into editing from an ile-tRNA synthetase structure with tRNAile and mupirocin. Science (1999) 285(5430):1074-1077.
   PubMed Web of Science ®Google Scholar